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Combination therapy of flucytosine (5FC) with other antifungal agents could be of use for the treatment of
invasive aspergillosis. However, interpretation of the results of in vitro interactions is problematic. The
fractional inhibitory concentration (FIC) index is the most commonly used method, but it has several major
drawbacks in characterizing antifungal drug interaction. Alternatively, a response surface approach using the
concentration-effect relationship over the whole concentration range instead of just the MIC can be used. We
determined the in vitro interactions between amphotericin B (AMB), itraconazole, and 5FC against 21
Aspergillus isolates with a broth microdilution checkerboard method that employs the dye MTT [3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide]. FIC indices based on three different MIC end-
points (MIC-0, MIC-1, and MIC-2) and the interaction coefficient alpha were determined, the latter by
estimation from the response surface approach described by Greco et al. (W. R. Greco, G. Bravo, and J. C.
Parsons, Pharmacol. Rev. 47:331–385, 1995). The value obtained for the FIC index was found to be dependent
on the MIC endpoint used and could be either synergistic, indifferent, or antagonistic. The response surface
approach gave more consistent results. Of the three combinations tested, the AMB-5FC combination was the
most potent in vitro against Aspergillus spp. We conclude that the use of the response surface approach for the
interpretation of in vitro interaction studies of antifungals may be helpful in order to predict the nature and
intensity of the drug interaction. However, the correlation of these results with clinical outcome remains
difficult and needs to be further investigated.
In the past 2 decades, the incidence of invasive aspergillosis
has increased. This increase is directly related to the growing
number of people at risk because of solid organ transplanta-
tion, hematopoietic stem cell transplantation, and intensified
chemotherapeutic regimens. Invasive aspergillosis is usually
caused by Aspergillus fumigatus and to lesser extent by Aspergil-
lus flavus, Aspergillus niger, and Aspergillus terreus (8, 18). The
morbidity and mortality of invasive aspergillosis remain high.
Amphotericin B (AMB) and itraconazole (ITZ) were the
only two antifungal agents available for the treatment of inva-
sive aspergillosis for a long period of time, but recently vori-
conazole was shown to be superior to AMB and other licensed
antifungal therapies for first-line treatment of invasive as-
pergillosis (11). Treatment with AMB is associated with neph-
rotoxicity, and resistance to AMB has been reported for A.
fumigatus (31), A. flavus (26), and A. terreus (3). The resistance
of A. fumigatus to ITZ, both in vitro and in vivo, has been
described previously (4, 6), and cross-resistance to antifungal
azoles was described for a clinical A. fumigatus isolate; MICs of
ITZ and voriconazole and of the investigational azoles ravu-
conazole and posaconazole for this isolate were high (32).
An alternative approach for the treatment of invasive as-
pergillosis could be the use of combination therapy. Combina-
tion therapy is successfully used for difficult-to-treat bacterial
infections, including mycobacterial infections (12), and viral
infections, including human immunodeficiency virus infection
(http://www.aidsinfo.nih.gov). Possible advantages of combina-
tion therapy are the improvement of the efficacy of antifungal
therapy due to synergistic drug interaction, the reduction of
drug levels required to produce the antifungal effect and con-
sequently the reduction of side effects, reduced risk for the
development of resistance, and possibly a shorter duration of
therapy (27). Of course, there are also possible disadvantages
of combination therapy, such as toxicity, negative drug inter-
action of the two drugs with each other or with other drugs,
and cost.
Flucytosine (5FC) is one of the oldest antifungal agents. It
was first synthesized in 1957 as a potential cytostatic agent.
However, it was ineffective against tumors but was found to
exert antifungal activity. The use of 5FC as a single agent is
limited to the treatment of cases of chromoblastomycosis, un-
complicated lower urinary tract candidiasis, and vaginal can-
didiasis due to the pretreatment occurrence of resistant strains
(about 10% of Candida albicans isolates) and the development
of resistance of many fungi during monotherapy. In the vast
majority of cases, 5FC is used concomitantly with other agents,
mainly AMB, for the treatment of systemic mycosis, such as
cryptococcosis, candidiasis, and aspergillosis. However, there is
no evidence that this combination is more effective than AMB
monotherapy in the treatment of both invasive candidal infec-
tions and invasive aspergillosis (29).
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In order to predict the nature as well as the intensity of the
drug interaction in clinical practice, in vitro susceptibility tests
such as checkerboard studies may be helpful, although results
of in vivo interactions, such as the toxicity of combined drugs,
cannot be determined. In addition, the interpretation of in
vitro interaction studies may be difficult (19). The concentra-
tion-effect relationship of antifungals extends over several two-
fold dilutions, instead of growth versus no growth, as is the case
for most antimicrobials. Consequently, the concentration at
which the MIC is read is arbitrary. The value and interpreta-
tion of the fractional inhibitory concentration (FIC) index suf-
fer from the same drawbacks. To overcome these disadvan-
tages, a surface response approach may be used. In that
approach, the whole interaction surface, i.e., all drug effects
either alone or in combination and not just the MIC effect, is
used to fit a model, and conclusions are drawn with respect to
a positive or negative interaction.
In this study we determined the in vitro interactions between
AMB and ITZ, AMB and 5FC, and ITZ and 5FC against 21
clinical Aspergillus isolates.
(Results of this investigation were partly presented at the
42nd Interscience Conference on Antimicrobial Agents and
Chemotherapy, San Diego, Calif., 2002.)
MATERIALS AND METHODS
Isolates. Twenty-one clinical Aspergillus isolates were tested: five ITZ-suscep-
tible (ITZ-S) A. fumigatus isolates (AZN 5161, AZN 7151, AZN 7319, AZN
7820, and AZN 8248), five ITZ-resistant (ITZ-R) A. fumigatus isolates (AZN 58,
AZN 59, AZN 5241, AZN 5242, and AZG 7), five A. flavus isolates (AZN 510,
AZN 6578, AZN 6686, AZN 6803, and AZN 6837), and six A. terreus isolates
(AZN 3a, AZN 10, AZN 18, AZN 27, AZN 30, and AZN 31). The isolates with
the AZN prefix were obtained from the private collection of the Department of
Medical Microbiology, University Medical Center Nijmegen, Nijmegen, The
Netherlands, and isolate AZG 7 was obtained from the University Hospital
Groningen, Groningen, The Netherlands (30). Isolates had been frozen in glyc-
erol broth at 80°C and were revived by subculturing them on Sabouraud
glucose agar tubes supplemented with 0.5% chloramphenicol and incubating
them for 5 to 7 days at 35°C. They were subcultured again on Sabouraud glucose
agar for 5 to 7 days at 35°C before preparation of the inoculum. All isolates were
tested in triplicate on different days.
Candida parapsilosis (ATCC 22019) and Candida krusei (ATCC 6258) were
used for quality control in all experiments.
Antifungal agents. AMB (Bristol-Myers Squibb, Woerden, The Netherlands),
ITZ (Janssen Pharmaceutica B.V., Tilburg, The Netherlands), and 5FC (ICN
Pharmaceuticals, Zoetermeer, The Netherlands) were obtained as powders.
AMB and ITZ were dissolved in dimethyl sulfoxide, and 5FC was dissolved in
distilled water to make stock solutions. The stock solutions were held at 80°C
until use. Serial twofold dilutions of each antifungal agent were prepared ac-
cording to NCCLS M38-A guidelines (23). Final dilutions were made in RPMI
1640 medium (with L-glutamine, without bicarbonate) (GIBCO BRL, Life Tech-
nologies, Woerden, The Netherlands) buffered to pH 7.0 with 0.165 mol of
3-[N-morpholino]propanesulfonic acid (MOPS) (Sigma-Aldrich Chemie GmbH,
Steinheim, Germany) per liter.
Susceptibility testing. MICs were determined by a modified broth microdilu-
tion method that employs the dye MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphe-
nyl-2H-tetrazolium bromide] (20). The final concentrations of all three antifun-
gal agents ranged from 0.016 to 16 g/ml. Because off-scale MICs were found for
5FC against the A. fumigatus and the A. terreus isolates, higher concentrations
(0.25 to 256 g/ml) were tested. Aliquots of 100 l of the drugs at a concentra-
tion of two times the targeted final concentration were dispensed in the wells of
flat-bottom 96-well microtiter plates (Costar, Corning, N.Y.).
Conidial suspensions were prepared spectrophotometrically (23) and were
further diluted in RPMI 1640 medium containing MTT (0.2 mg/ml; Sigma
Chemical Co., St. Louis, Mo.). In order to obtain a final inoculum concentration
of 0.4  104 to 5  104 CFU/ml and a final MTT concentration of 0.1 mg/ml (at
this concentration MTT has no effect on the growth of the fungi [20]), 100 l of
the inoculum was added to the wells. The microtiter plates were incubated for
48 h at 35°C.
After 48 h, the content of each well was removed, and 200 l of isopropanol
containing 5% HCl (1 N) was added to extract the dye. After 30 min of incuba-
tion at room temperature and gentle agitation, the optical density at 540 nm
(OD540) was measured with a microplate reader (Anthos htIII; Anthos Labtec
Instruments, Salzburg, Austria). The ODs of the blank wells were subtracted
from the ODs of the inoculated wells.
The percentage of MTT conversion to its formazan derivate for each well was
calculated by comparing the OD540 of the well with that of the drug-free control
based on the following equation: (OD540 of the well that contained the drug/
OD540 of the drug-free well)  100%.
For AMB, the lowest concentration that showed 10% or less of the growth of
the growth control (MIC-0) was taken as MIC endpoint (21). For ITZ and 5FC,
the lowest concentration that showed 50% or less of the growth of the growth
control (MIC-2) was taken as MIC endpoint.
Interaction of drugs in vitro. Drug interactions were assessed by a modified
checkerboard broth microdilution method that employs the dye MTT. The final
concentration of the antifungal agents ranged from 0.016 to 16 g/ml for AMB,
from 0.008 to 8 g/ml for ITZ, and from 0.062 to 64 g/ml for 5FC.
Aliquots of 50 l of each drug (and in the case of the single-drug control, 50 l
of that drug and 50 l of medium with the drug solvent at the final concentration)
at a concentration four times the targeted final concentration were dispensed in
the wells in order to obtain a two-dimensional checkerboard.
Conidial suspensions were prepared as described above, and 100 l of the
inoculum was added to the wells. The microtiter plates were incubated for 48 h
at 35°C. After 48 h, the conversion of MTT was measured as described above.
Drug interaction modeling. The data obtained were analyzed using two dif-
ferent models. The models were nonparametric and parametric approaches of
the Loewe additivity zero-interaction theory.
FIC index model. The FIC index, which is the nonparametric approach, was
defined as follows (22): FIC FICA FICB (MIC of drug A in combination/
MIC of drug A alone)  (MIC of drug B in combination/MIC of drug B alone).
Since each triplicate experiment yielded several FICs, among all FICs
calculated for each replicate, the minimum FIC (FICmin) and maximum FIC
(FICmax) were determined to correspond to the lowest and the highest FIC,
respectively. The reported FIC index was the FICmin in all cases unless the
FICmax was higher than 4, and then the FICmax was reported as the FIC index.
In order to determine the larger departure from additivity, the FICmax was also
reported as the FIC index for data sets where the FICmax was smaller than 4 but
the FICmin was greater than 1. If for a data set the FICmin was lower than 0.5
and the FICmax was higher than 4, both the FICmin and the FICmax were
reported.
The three MIC endpoints used, namely, MIC-0, MIC-1, and MIC-2, were
defined as the lowest drug concentrations showing no more than 10, 25, and 50%
of the growth of the growth control, respectively. Thus, the following FIC indices
were determined for each replicate: FIC-0, FIC-1, and FIC-2, respectively. Off-
scale MICs were converted to the next-higher or -lower twofold concentration.
Since the FIC index is not normally distributed, the median and the range of the
FIC indices among the replicates were calculated. For the interpretation of the
results obtained with the FIC index, we considered the results of all three
replicates as one outcome. Thus, when the FIC indices from all three replicates
were smaller than 1, synergism was claimed. When the FIC indices from all three
replicates were higher than 1, antagonism was claimed, and in all other cases,
indifference was concluded.
Greco model. The fully parametric surface approach described by Greco et al.
(9) was based on the following equation:
1
DA
IC50, A EEcon E
1/mA
DB
IC50, B EEcon E
1/mB
 
DADB
IC50, AIC50, B EEcon E
0.51/mA1/mB	
where E is the percentage of growth (dependent variable) at the drug concen-
trations DA and DB (independent variables), Econ is the maximal percentage of
growth observed in the drug-free control, IC50,A and IC50,B are the inhibitory
concentrations of drug A and drug B producing 50% of the Econ, mA and mB are
the slopes of the concentration-effect curves (Hill coefficient) for drug A and
drug B, and  is the interaction parameter (IC) which describes the nature of
the interaction. This model was fitted directly to the entire data set (percentages
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of growth for all concentrations of the two drugs alone or in combination) by
using a nonweighted, nonlinear regression analysis and a computer program
(ModLab; Medimatics, Maastricht, The Netherlands). The program estimates
the model parameters, and it also calculates the 95% confidence interval (95%
CI) for each parameter. Goodness-of-fit criteria included the R2. Obtained pa-
rameters were validated using the program Syner, kindly provided to us by G. L.
Drusano (Albany Medical College, Albany, N.Y.).
The median and the range of the IC among the replicates were calculated.
For the interpretation of the results obtained with the Greco model, we consid-
ered the results of all three replicates as one outcome. Thus, when the IC was
higher than 0 for all three replicates, synergism was claimed. When the IC was
lower than 0 for all three replicates, antagonism was claimed. In all other cases,
indifference was concluded.
RESULTS
All Aspergillus isolates grew well after 48 h of incubation at
35°C. In each batch of broth microdilution tests, the MICs of
the quality control strains were within the reference ranges.
MIC data. Table 1 shows the results of the susceptibility
testing of AMB, ITZ, and 5FC against the Aspergillus isolates.
The MICs of AMB ranged from 0.125 to 2 g/ml, with the MIC
at which 50% of the isolates tested were inhibited (MIC50)
being 0.5 g/ml. The MICs of ITZ ranged from 
0.016 to
16 g/ml, with the MIC50 being 0.125 g/ml, and the MICs
of 5FC ranged from 
0.25 to 256 g/ml, with the MIC50
being 4 g/ml.
In vitro interactions. Table 2 shows the results obtained with
the FIC index model and the Greco model for each species-
drug combination. The results, and sometimes also the inter-
actions, found by both the FIC index model and the Greco
model depended on the species tested. Importantly, the results
and conclusions drawn from the FIC index model depended
primarily on the MIC endpoint used. The results of the various
FIC indices were, however, not completely contradictory, in
that for all data sets for which the FICmin was reported, the
FICmax was lower than or equal to 2.5, and for all data sets for
which the FICmax was reported, the FICmin was greater than
or equal to 0.5. The difference between the FICmin and the
FICmax never ranged from 
0.5 to 4.
AMB-ITZ combination and the FIC index model. Depend-
ing on the definition of the FIC used (FIC-0, FIC-1, or FIC-2),
a synergistic, indifferent, or antagonistic interaction was found
with a significant portion of the isolates (Table 2). Both the
FIC-0 and the FIC-1 for the A. flavus isolates were significantly
higher (P 
 0.05) than those for the ITZ-S A. fumigatus, the
ITZ-R A. fumigatus, and the A. terreus isolates. The FIC-2 for
the ITZ-R A. fumigatus isolates were significantly lower than
those for the A. flavus and the ITZ-S A. fumigatus isolates, and
the FIC-2 for the A. terreus isolates were significantly lower
than those for the A. flavus isolates.
Greco model. Regarding the goodness of fit, the R2s were
above 0.90 in the majority of cases (median, 0.93; range, 0.07 to
0.98).
Antagonism was found with 33.3%, indifference was found
with 57.2%, and synergism was found with 9.5% of all 21
isolates. The IC values for the ITZ-R A. fumigatus isolates
TABLE 1. Results of the susceptibility testing of AMB, ITZ, and 5FC against several Aspergillus isolates
Species
(no. of isolates)
MIC50 (g/ml) (range)
a
AMB ITZ 5FC
ITZ-S A. fumigatus (5) 0.25 (0.25) 0.125 (
0.016–0.25) 8 (2–128)
ITZ-R A. fumigatus (5) 0.25 (0.125–1) 4 (0.5–16) 16 (2–256)
A. flavus (5) 0.5 (0.25–0.5) 0.125 (
0.016–0.25) 2 (0.25–4)
A. terreus (6) 1 (0.5–2) 0.031 (
0.016–0.062) 1.5 (
0.25–256)
a MIC50 and range are shown for three replicate experiments. For AMB, MIC-0 was used. For ITZ and 5FC, MIC-2 was used.
TABLE 2. Summarized results of the two drug interaction models for the AMB-ITZ, AMB-5FC, and
ITZ-5FC combinations for several Aspergillus isolatesc
Drug combination Species
Nonparametric result (FIC index)a Parametric result
(Greco IC)bFIC-0 FIC-1 FIC-2
AMB-ITZ ITZ-S A. fumigatus 2.06 (0.53–2.50) 0.63 (0.53–2.25) 0.55 (0.09–0.63) 0.02 (0.04–0.01)
ITZ-R A. fumigatus 2.50 (0.50–2.50) 0.56 (0.38–2.06) 0.25 (0.09–0.50) 1.05  102 (1.57–1.50  106)
A. flavus 4.13 (0.63–4.50) 2.25 (0.52–4.25) 0.53 (0.31–2.50) 0.06 (0.07–0.00)
A. terreus 2.25 (0.53–4.25) 0.53 (0.52–2.25) 0.25 (0.19–1.50) 0.01 (0.07–0.58)
AMB-5FC ITZ-S A. fumigatus 0.50 (0.50–1.00) 0.56 (0.38–1.00) 0.54 (0.19–1.00) 2.88 (0.25–3.23  104)
ITZ-R A. fumigatus 0.53 (0.50–1.00) 0.52 (0.50–2.00) 0.28 (0.09–0.75) 2.83 (0.00–17.49)
A. flavus 0.51 (0.26–0.75) 0.56 (0.28–4.13) 0.63 (0.27–4.06) 0.09 (0.08–3.54)
A. terreus 2.01 (0.27–4.02) 0.22 (0.06–2.50) 0.31 (0.04–1.50) 2.20 (2.06–2.34  1011)
ITZ-5FC ITZ-S A. fumigatus 2.50 (1.00–8.50) 1.50 (0.50–2.50) 0.26 (0.16–2.06) 0.21 (7.97–1.69  1010)
ITZ-R A. fumigatus ND ND ND 8.21  102 (1.00–2.49  1011)
A. flavus 0.75 (0.25–2.25) 1.00 (0.31–2.50) 0.56 (0.19–2.50) 0.04 (0.09–2.09)
A. terreus 4.50 (2.50–8.50) 2.50 (0.16–4.50) 0.44 (0.14–1.00) 0.06 (0.32–4.51  103)
a Three FIC indices were determined, namely, FIC-0, FIC-1, and FIC-2, using three different MIC endpoints. For ITZ-5FC, the FIC-0, FIC-1, and FIC-2 for the
ITZ-R A. fumigatus isolates could not be determined due to full growth of the plate. ND, could not be determined.
b For the data sets in which the 95% CI did overlap 0, 0 was used as the IC.
c The data are medians and ranges for three replicate experiments.
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were significantly higher than those for the A. flavus, the ITZ-S
A. fumigatus, and the A. terreus isolates, and the IC values for
the A. terreus and the ITZ-S A. fumigatus isolates were signif-
icantly higher than those for the A. flavus isolates.
AMB-5FC combination and the FIC index model. Depend-
ing on the definition of the FIC used (FIC-0, FIC-1, or FIC-2),
a synergistic, indifferent, or antagonistic interaction was found
with a significant portion of the isolates (Table 2). For both the
FIC-0 and the FIC-1, the median MIC (MIC50) of 5FC for all
isolates together decreased from 128 g/ml when it was used
alone to 4 g/ml when it was used in combination with AMB.
For the A. terreus isolates, the FIC-0 values were significantly
higher and the FIC-1 values were significantly lower than those
for the ITZ-S A. fumigatus, the ITZ-R A. fumigatus, and the A.
flavus isolates. When the FIC-2 was used, the MIC50 of 5FC for
all isolates together decreased from 16 g/ml when it was used
alone to 1 g/ml when it was used in combination with AMB.
The FIC-2 values for the ITZ-R A. fumigatus and the A. terreus
isolates were significantly lower than those for the A. flavus and
the ITZ-S A. fumigatus isolates.
Greco model. The R2s were above 0.90 in the majority of
cases (median, 0.95; range, 0.58 to 0.98). Antagonism was
found with 4.8%, indifference was found with 33.3%, and syn-
ergism was found with 61.9% of all 21 isolates. The IC values
for the A. flavus isolates were significantly lower than those for
the ITZ-S A. fumigatus, the ITZ-R A. fumigatus, and the A.
terreus isolates.
ITZ-5FC combination and the FIC index model. Depending
on the definition of the FIC used (FIC-0, FIC-1, or FIC-2), a
synergistic, indifferent, or antagonistic interaction was found
with a significant portion of the isolates (Table 2). The differ-
ences between the FIC-0 values for the ITZ-S A. fumigatus, the
A. flavus, and the A. terreus isolates were significant. The high-
est FIC-0 values were found for the A. terreus isolates, followed
by the ITZ-S A. fumigatus isolates and then by the A. flavus
isolates. The FIC-1 values for the A. flavus isolates were sig-
nificantly lower than those for the A. terreus isolates. The FIC-2
values for the A. flavus isolates were significantly higher than
those for the A. terreus and the ITZ-S A. fumigatus isolates.
Greco model. The R2 of all fits ranged from 0.40 to 0.95
(median, 0.83). Antagonism was found with 23.8%, indiffer-
ence was found with 66.7%, and synergism was found with
9.5% of all 21 isolates. The IC values for the ITZ-S A. fu-
migatus isolates were significantly lower than those for the
ITZ-R A. fumigatus, the A. flavus, and the A. terreus isolates.
Effect of MIC endpoint on FIC index values. Since MICs of
various drugs were determined at three endpoints, MIC-0,
MIC-1, and MIC-2, FIC indices calculated were different de-
pending on the endpoint used (FIC-0, FIC-1, and FIC-2).
Figure 1 shows the interpretations resulting from the three
different endpoints. It is clear from the figure that the value of
the FIC index, and therefore the conclusions based thereon, is
directly dependent on the endpoint used.
DISCUSSION
Determining the in vitro interaction between antifungals
depends on the methodology used and certain variables, such
as inoculum size and preparation, and on the approach used to
analyze the results.
Previous studies in which the in vitro interactions between,
for example, AMB and ITZ against Aspergillus species were
determined yielded conflicting results (5, 15, 17, 28). This lack
of agreement might be caused by differences in the methods
used (agar dilution method, E-test, macrodilution method, and
microdilution method) or by differences in variables such as
inoculum size (which varies from 103 to 105 CFU/ml), ways of
preparing the inoculum (hemacytometer or spectrophotome-
ter), incubation times (24 to 48 h), incubation temperatures (30
to 37°C), and media (yeast nitrogen base or RPMI 1640). In
this study we used a colorimetric broth microdilution checker-
board method, based on the conversion of the tetrazolium salt
MTT to its formazan derivative, to determine the in vitro
FIG. 1. Interactions found by using different MIC endpoints for the
determination of the FIC index for the AMB-ITZ (a), the AMB-5FC
(b), and the ITZ-5FC (c) combinations. Shaded, antagonism; black,
indifference; white, synergism.
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interactions. This method is very sensitive, since it quantifies
small amounts of fungal growth, and it is objective in contrast
to visual reading of the turbidity, which makes the precise
quantification of the hyphal growth of molds possible.
Another important reason for the different results and con-
clusions found in previous in vitro interaction studies might be
the approach used to analyze the results. The most commonly
used method is the calculation of the FIC index, but this
approach has several major drawbacks. The first and principal
problem in determining the FIC index is the choice of the MIC
endpoints to be used for the two drugs alone and in combina-
tion (28). For antibiotics, complete inhibition of growth is used
as the endpoint, and the difference between wells showing
turbidity (no effect) and wells showing no turbidity (a maxi-
mum effect) is not more than 1 dilution. However, the concen-
tration-effect relationship in MIC determinations for antifun-
gals covers a range of dilutions, and the choice of the MIC
endpoint is therefore more arbitrary. In addition, trailing ef-
fects are sometimes present. This problem especially arises
when combinations of drugs with different MIC endpoints,
such as the AMB-ITZ and AMB-5FC combinations, are used.
For AMB, MIC-0 is taken as the endpoint, whereas MIC-1 or
MIC-2 is taken as the endpoint for both ITZ and 5FC (23).
When AMB is combined with ITZ or 5FC, the question arises
of which MIC endpoint should be used: MIC-0, MIC-1, or
MIC-2. In this study, the FIC index value found depended
primarily on the MIC endpoint used for all three combinations
(Fig. 1). In almost all cases, the differences between the FIC-0,
the FIC-1, and the FIC-2 values were significant (P 
 0.05).
For all three combinations, the highest FIC index value was
found with the FIC-0, followed by the FIC-1 and then by the
FIC-2. Therefore, the weakest positive or the strongest nega-
tive interaction was found with the FIC-0, whereas the stron-
gest positive or the weakest negative interaction was found
with the FIC-2. For both the AMB-ITZ and the ITZ-5FC
combinations, even the interaction found depended on the
MIC endpoint used. When MIC-0 was used as the endpoint,
antagonism was found; indifference was found when MIC-1
was used as the endpoint, and synergism was found when
MIC-2 was used.
Another drawback of the FIC index model is the summary
parameter and its interpretation. In this study, the FICmin
was reported as the FIC index in all cases unless the FICmax
was higher than 4; in these cases, the FICmax was reported as
the FIC index. The FICmax was also reported as the FIC
index for data sets where the FICmax was smaller than 4 but
the FICmin was greater than 1. If for a data set the FICmin
was lower than 0.5 and the FICmax was higher than 4, both
the FICmin and the FICmax were reported. A problem of
this approach is that one index (the FIC index), based on the
results of one well, is used to describe the whole checkerboard;
more refinement may be necessary, since at some concentra-
tions there may be synergism but at others there may be indif-
ference or even antagonism. A solution might be the calcula-
tion of the average FIC index and its 95% CI among all FIC
indices of a data set. Furthermore, outliers can affect the re-
sults.
Two approaches can be used to interpret the results of the
FIC index model. The first approach looks at the results of
each of the three replicates separately and determines the
interaction. For the interpretation of the FIC index, several
different definitions have been described in the literature (1,
22, 24), but there is no consensus on which definition to use in
interaction studies. In most cases, synergy was claimed when
the FIC index was lower than or equal to 0.5, and antagonism
was claimed when the FIC index was higher than 4. In all other
cases, indifference was concluded. These cutoffs were chosen in
order to diminish the effect of the intraexperimental error (1
dilution) of antifungal susceptibility testing, since a twofold
dilution scheme was followed. In the approach that we used,
the results of the three replicates were interpreted as one
outcome (synergism, antagonism, or indifference), thereby
constraining the interexperimental error. Thus, when the re-
sults of all three replicates were concordant, synergism or
antagonism was claimed if the FIC indices were below 1 or
above 1, respectively. In all other cases, indifference was con-
cluded. An alternative approach would be to use the mean of
the results from three replicates and the 95% CI; if 1 does not
include the 95% CI, significant synergism or antagonism could
be concluded. However, because the distribution of the FIC
index is not normal, we preferred the approach mentioned.
Assessing the nature of drug interactions using the FIC
index model faces several other problems besides the choice of
the MIC endpoint, the lack of a good summary parameter, and
the interpretation of this parameter, such as the difficulty in
statistically interpreting the results and the imprecise approx-
imation of the real FIC index when off-scale MICs are present
(this situation was seen in this study for the ITZ-R A. fumigatus
isolates with the combination of ITZ and 5FC).
Many of the above-mentioned problems of the FIC index
can be overcome by using a response surface approach, which
is fitted to the whole response surface. The use of a model fit
makes an arbitrarily chosen endpoint unnecessary, allows the
optimal use of information from the data, allows the determi-
nation of error estimates of the interaction coefficient and
thereby indicates whether the interaction is significant or not,
and allows an objective statistical criterion. Such a model was
developed by Greco et al. (9) and has already been successfully
used in the field of anticancer and antiviral drug interactions.
It is a fully parametric model which is based on the assumption
that the concentration-effect curves follow the Emax model
(sigmoid curve with variable slopes) and which includes statis-
tical significance levels of the interactions and summarizes
them with a nonunit, concentration-independent interaction
parameter.
There are also two approaches for the interpretation of
results obtained with the Greco model. The first approach
looks at the results of each of the three replicates separately
and determines the interaction. If the estimate of IC is pos-
itive and the 95% CI does not overlap 0, the interaction is
significantly synergistic. If the estimate of IC is negative and
the 95% CI does not overlap 0, the interaction is significantly
antagonistic. In all other cases, indifference is concluded. In
the approach that we used, the results of all three replicates
were considered as one outcome (synergism, antagonism, or
indifference). Thus, when the results of all three replicates
were concordant, synergism or antagonism was claimed if the
estimate of the IC was above or below 0, respectively. In all
other cases, indifference was concluded.
In this study, differences were found between the FIC index
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model and the Greco model. These differences could have
been caused by the drawbacks of the FIC index, which we
already mentioned, but also by the drawbacks of the Greco
model (19). The first problem is that the Greco model does not
describe precisely the entire response surface, as statistically
significant deviations from the model were found. This was
more pronounced in combinations where trailing phenomena
were apparent or with very strong synergistic interactions. In
the first case, the Emax model does not adequately describe the
data, while in the latter case a part of the problem is the
heterogeneity of the data. In these cases, the levels of growth
at each combination were overestimated by the Greco model
compared with the growth that was observed. Another prob-
lem is that, because of the nature of the model, the estimates
obtained are less reliable for antagonistic interactions. For
these interactions, the Greco model tends to produce an esti-
mate higher than the observed effect at high concentrations,
which is an innate property of the model. The Greco model
also provides only one IC value to describe the interaction,
but the assumption that only one interaction can take place
when two drugs are combined is disputed because interactions
in which both synergism and antagonism were present at dif-
ferent concentrations of the two drugs have been described (2,
10). However, to calculate this IC value and thus determine
the interaction, the model incorporates interaction data from
all wells of the checkerboard. Finally, statistically significant
results of the response surface fit do not necessarily indicate
clinical significance. An IC value ( the 95% CI) of 0.03
(0.01), for example, would indicate statistically significant
antagonism. However, the clinical interpretation remains to be
elucidated. As is true for all tests and their outcomes, test
results must be related to the clinical outcome with respect to
the interaction found, the side effects, the costs, etc. However,
at least these decisions can be made by a test result that is more
objective than that obtained by the FIC index.
In an earlier published study (28), we found that there was
a correlation between the IC values and the FIC indices. This
was confirmed by J. Meletiadis et al. (unpublished data). To
determine whether the value of the IC could predict the
magnitude of the FIC index, Meletiadis et al. analyzed the
negative and positive IC values with their corresponding FIC
indices separately. A statistically significant correlation was
found for the positive IC values and the corresponding FIC
indices, while for the negative IC values and the correspond-
ing FIC indices no statistically significant correlation was
found. So, it seems that there is a correlation between the IC
values and the FIC indices when there is a positive interaction
(synergism) but not when there is a negative interaction (an-
tagonism), although the exact quantitative relationship is not
clear. This can be due to either the FIC index or the Greco
model.
Further investigation in order to find the best model for
determining the in vitro interaction of antifungal drugs should
be performed. However, we consider the limitations of the FIC
index model, in particular the arbitrary results, to be far
greater than those of the Greco model in characterizing anti-
fungal drug interactions.
Although we found some differences between the results of
the FIC index model and the Greco model and between the
different Aspergillus species tested, the combination of AMB
with 5FC was the most potent against Aspergillus species in
vitro. Previous in vitro studies showed that this combination
was mostly additive or synergistic against Aspergillus species (7,
13, 14, 16, 25). However, in one study antagonism was observed
(5). These seemingly contradicting results may have been due
to the methods used in those studies, the FIC index, or the
interpretation thereof. It must be realized, however, that no
clear correlation has been shown between the in vitro syner-
gism of AMB and 5FC and the in vivo outcome of aspergillus
infections. These are highly warranted.
We conclude that the use of the response surface approach
for the interpretation of in vitro interaction studies of antifun-
gals may be helpful in order to predict the nature and intensity
of the drug interactions. However, the correlation of these
results with clinical outcomes remains difficult and needs to be
further investigated.
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